Live Breaking News & Updates on One Federal Street
Stay updated with breaking news from One federal street. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock July 13, 2021 20:30 ET | Source: Celldex Therapeutics, Inc. Celldex Therapeutics, Inc. Needham Heights, Massachusetts, UNITED STATES HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 892,857 shares of common stock at the public offering price, less underwriting discounts and commissions. Jefferies, SVB Leerink, Guggenheim Securities and Cantor are acting as the joint book-running managers for the offering. LifeSci Capital LLC and H.C. Wainwright & Co. are acting as co-l ....
Imara Announces Launch of Proposed Public Offering apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock ZENTALIS PHARMACEUTICALSJune 29, 2021 GMT NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pricing of an underwritten public offering of 3,100,000 shares of its common stock at a public offering price of $48.50 per share, for total gross proceeds of approximately $150.4 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on July 1, 2021, subject to customary closing conditions. In addition, Zentalis has granted the underwriters a 3 ....
NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pricing of an underwritten public offering of 3,100,000 shares of its common stock at a public offering price of $48.50 per share, for total gross proceeds of approximately $150.4 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on July 1, 2021, subject to customary closing conditions. In addition, Zentalis has granted the underwriters a 30-day option to purchase up to an additional 465,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. ....
Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock June 28, 2021 21:09 ET | Source: ZENTALIS PHARMACEUTICALS ZENTALIS PHARMACEUTICALS New York, New York, UNITED STATES NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pricing of an underwritten public offering of 3,100,000 shares of its common stock at a public offering price of $48.50 per share, for total gross proceeds of approximately $150.4 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on July 1, 2021, subject to customary closing conditions. In addition, ....